---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-041568"
form_type: "8-K"
ticker: "CARM"
cik: "0001485003"
company_name: "Carisma Therapeutics Inc."
filed_at: "2024-04-01T23:59:59+00:00"
generated_at: "2026-06-04T04:30:54.377305+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Carisma Therapeutics reports $86.9M net loss; prioritizes CT-0525, cuts workforce 37%

## Summary
- Cash of $77.6M as of Dec 31, 2023, expected to fund operations into Q3 2025 after restructuring.
- R&D expenses were $74.1M in 2023 (up from $56.6M); net loss $86.9M vs $61.2M in 2022.
- Prioritizing CT-0525 (anti-HER2 CAR-Monocyte); ceasing new enrollment in CT-0508 study; pausing CT-1119.
- Workforce reduction of ~37% in Q2 2024 as part of pipeline reprioritization and cost savings.
- Appointed John Hohneker, M.D. to board, effective April 1, 2024; Chidozie Ugwumba resigned.

## SEC filing metadata
- accession: 0001104659-24-041568
- form_type: 8-K
- ticker: CARM
- cik: 0001485003
- company_name: Carisma Therapeutics Inc.
- filed_at: 2024-04-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1485003/000110465924041568/0001104659-24-041568-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1485003/000110465924041568/tm2410111d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-041568
- JSON: https://secwatch.observer/filing/0001104659-24-041568.json
- Plain text: https://secwatch.observer/filing/0001104659-24-041568.txt

## Key facts
- Earnings Releases
  Carisma Therapeutics Inc. reported financial results for fourth quarter and full year ended December 31, 2023.
  - Period: fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: On April 1, 2024, Carisma Therapeutics Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1485003/000110465924041568/0001104659-24-041568-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.